ReviewCureus2025
Cracking the Code of Colorectal Cancer Screening: An Overview With a Focus on Current and Emerging Screening Methods.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research advances in early screening for colorectal cancer (Review).Molecular and clinical oncology · 2026Review
- The Importance of 14-3-3 Proteins in Colorectal Cancer Regulation: Mechanisms of Function and Clinical Opportunities.BioMed research international · 2026Review
- Exosomal microRNAs in colorectal cancer communication networks: implications for metastasis, therapy resistance, and precision medicine.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common cancer that affects the colon and rectum. It is a major cause of cancer-related mortality. A complicated interaction between environmental and genetic factors, such as age, diet, gut microbiota, obesity, chronic inflammation, and familial predisposition, appears to contribute to the pathophysiology of colorectal cancer. A multidisciplinary strategy is necessary for the effective care of CRC, including early detection through screening, surgical resection, chemotherapy, radiation therapy, and targeted medicines. The slow progression of CRC through various stages gives us, physicians, leverage and a chance to promptly and adequately screen a patient and give them a better chance at life. There are multiple clinical trials being conducted to find better and the best screening and treatment modalities. Existing and emerging screening tests can be broadly divided into blood-based, stool-based and direct imaging-based screening tests. Colonoscopy is the gold standard. However, numerous emerging screening tests are changing the face of colon cancer screening. This review aims to highlight the background of CRC, including its etiopathogenesis, risk factors, and clinical features. It will also shed light on the existing and emerging screening techniques that will decide the future of this deadly cancer. In addition, the management section of this article will provide a summary of suggestions, including radiation and medical and surgical treatment modalities that may benefit physicians in managing this challenging condition. We conducted a comprehensive literature search in PubMed-indexed journals using the terms "Colorectal Cancer," "Etiopathogenesis of CRC," and "Emerging screening and treatment modalities in CRC." We explored the literature on the background of CRC, its pathogenesis, the importance of screening, screening modalities and comparisons amongst each one, and treatment options for this challenging cancer. We used peer-reviewed original research articles and systematic reviews published in English, conducted from 2015 to the present time, to reflect the developments in colorectal cancer. Studies with uncertain methodological details and outcomes were excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.